BlackRock Amends Viridian Therapeutics Stake, Signals Confidence
Ticker: VRDN · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1590750
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech
TL;DR
**BlackRock still owns Viridian Therapeutics, good sign for stability.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Viridian Therapeutics, Inc.\DE as of December 31, 2023. This filing indicates that BlackRock, a major institutional investor, continues to hold a significant stake in Viridian Therapeutics. For investors, this signals continued institutional confidence in Viridian Therapeutics, which could be a positive indicator for the stock's stability and future performance.
Why It Matters
This filing shows that a major institutional investor, BlackRock, maintains a position in Viridian Therapeutics, which can reassure current and potential investors about the company's long-term prospects.
Risk Assessment
Risk Level: low — The filing indicates continued institutional ownership, which generally reduces risk by signaling confidence from a large, sophisticated investor.
Analyst Insight
Investors should note BlackRock's continued stake as a sign of institutional interest, but this filing alone doesn't provide new information on share count or percentage, so further due diligence on Viridian Therapeutics' fundamentals is still warranted.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Viridian Therapeutics, Inc.\DE (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A
- 92790C104 (other) — the CUSIP number for Viridian Therapeutics' Common Stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Which company is the subject of this filing?
The subject company is Viridian Therapeutics, Inc.\DE, with a CIK of 0001590750.
Who is the reporting person in this filing?
The reporting person, or the entity that filed this statement, is BlackRock Inc., with a CIK of 0001364742.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Viridian Therapeutics, Inc.\DE (VRDN).